Cargando…
A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa UK Ltd.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862070/ https://www.ncbi.nlm.nih.gov/pubmed/23617228 http://dx.doi.org/10.3109/14767058.2013.799650 |
_version_ | 1782295714182725632 |
---|---|
author | Hod, Moshe Mathiesen, Elisabeth R Jovanovič, Lois McCance, David R Ivanisevic, Marina Durán-Garcia, Santiago Brøndsted, Lise Nazeri, Avideh Damm, Peter |
author_facet | Hod, Moshe Mathiesen, Elisabeth R Jovanovič, Lois McCance, David R Ivanisevic, Marina Durán-Garcia, Santiago Brøndsted, Lise Nazeri, Avideh Damm, Peter |
author_sort | Hod, Moshe |
collection | PubMed |
description | OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were randomized to IDet (n = 152) or NPH (n = 158) ≤12 months before pregnancy or at 8–12 gestational weeks. RESULTS: For IDet and NPH, there were 128 and 136 live births, 11 and 9 early fetal losses, and two and one perinatal deaths, respectively. Gestational age at delivery was greater for children from the IDet arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88], p = 0.012, linear regression). Sixteen children had a malformation (IDet: n = 8/142, 5.6%; NPH: n = 8/145, 5.5%). The incidence of adverse events was similar between treatments. CONCLUSION: IDet is as well tolerated as NPH as regards perinatal outcomes in pregnant women with type 1 diabetes and no safety issues were identified. |
format | Online Article Text |
id | pubmed-3862070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Informa UK Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-38620702013-12-16 A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes Hod, Moshe Mathiesen, Elisabeth R Jovanovič, Lois McCance, David R Ivanisevic, Marina Durán-Garcia, Santiago Brøndsted, Lise Nazeri, Avideh Damm, Peter J Matern Fetal Neonatal Med Original Article OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were randomized to IDet (n = 152) or NPH (n = 158) ≤12 months before pregnancy or at 8–12 gestational weeks. RESULTS: For IDet and NPH, there were 128 and 136 live births, 11 and 9 early fetal losses, and two and one perinatal deaths, respectively. Gestational age at delivery was greater for children from the IDet arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88], p = 0.012, linear regression). Sixteen children had a malformation (IDet: n = 8/142, 5.6%; NPH: n = 8/145, 5.5%). The incidence of adverse events was similar between treatments. CONCLUSION: IDet is as well tolerated as NPH as regards perinatal outcomes in pregnant women with type 1 diabetes and no safety issues were identified. Informa UK Ltd. 2014-01 2013-06-04 /pmc/articles/PMC3862070/ /pubmed/23617228 http://dx.doi.org/10.3109/14767058.2013.799650 Text en © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. |
spellingShingle | Original Article Hod, Moshe Mathiesen, Elisabeth R Jovanovič, Lois McCance, David R Ivanisevic, Marina Durán-Garcia, Santiago Brøndsted, Lise Nazeri, Avideh Damm, Peter A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title | A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title_full | A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title_fullStr | A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title_full_unstemmed | A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title_short | A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes |
title_sort | randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine hagedorn in type 1 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862070/ https://www.ncbi.nlm.nih.gov/pubmed/23617228 http://dx.doi.org/10.3109/14767058.2013.799650 |
work_keys_str_mv | AT hodmoshe arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT mathiesenelisabethr arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT jovanoviclois arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT mccancedavidr arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT ivanisevicmarina arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT durangarciasantiago arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT brøndstedlise arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT nazeriavideh arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT dammpeter arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT hodmoshe randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT mathiesenelisabethr randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT jovanoviclois randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT mccancedavidr randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT ivanisevicmarina randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT durangarciasantiago randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT brøndstedlise randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT nazeriavideh randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes AT dammpeter randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes |